Beam Therapeutics Inc. (BEAM) is a leading-edge biotechnology company that is involved in the development and commercialization of innovative gene therapies. The company's headquarters are located in Cambridge, Massachusetts, at the heart of one of the world's densest clusters of biotechnological innovations.
Established under the guidance of some of the most recognized leaders in the fields of molecular genetics and genomics, like David R. Liu, Feng Zhang, and J. Keith Joung, BEAM possesses the foundational CRISPR gene-editing patents. The company revolutionizes medicine with its commitment to developing gene therapies, that use base editing to treat serious illnesses.
BEAM's approach differs from conventional gene therapy, which can often have unintentional and potentially harmful consequences. The company's transformative base editing technology introduces precise, predictable, and controllable genetic changes at the molecular level. This involves changing the 'letters' of the DNA or RNA inside a cell to either correct a disease-causing error, or make a beneficial change. The proprietary base editing platforms are designed for high precision and enhanced safety.
Currently, BEAM's primary focus is on developing treatments for serious diseases such as sickle cell disease and beta-thalassemia that have limited therapeutic alternatives. Moreover, the company’s pipeline includes editing therapies for genetic and liver diseases, ocular diseases, and oncology.
Beam Therapeutics Inc., since its inception, has raised capital through an initial public offering (IPO) and private investments. The company debuted its IPO in February 2020 on the NASDAQ under the ticker BEAM, and it raised over $200 million.
BEAM continues to make advancements in genetic medicines utilizing one of the most advanced genomic editing technologies. With its strategic partnerships, skilled team, and robust financial standing, Beam Therapeutics is well-positioned to innovate and transform the genomic medicine landscape.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Beam Therapeutics reported a wider net loss of $134.405 million in Q3 2026, compared to $112.571 million in the same quarter last year, with license and collaboration revenue significantly decreasing. Despite the financial loss, the company holds $1.0 billion in cash, cash equivalents, and marketable securities, which it expects will fund operations for at least the next 12 months. Beam Therapeutics also provided updates on its clinical pipeline, including positive data from its BEAM-302 trial for AATD, BEAM-301 for GSDIa, and progress in its risto-cel program for sickle cell disease.
Beam Therapeutics Inc. (BEAM) reported a Q3 loss of $1.28 per share, missing the Zacks Consensus Estimate of $1.17, and revenues of $0.31 million, significantly below the $9.7 million from the previous year and the Zacks Consensus Estimate by 97.23%. The company's stock has underperformed the S&P 500 this year, leading to a Zacks Rank #4 (Sell) based on an unfavorable earnings outlook. Investors are advised to monitor future estimate revisions for potential stock movement.
Bank of America Securities analysts have provided updated ratings and price targets for several healthcare companies. Jason Zemansky reiterated a Hold rating on Biogen (BIIB) with a $255.00 price target, while Alec Stranahan maintained a Buy rating on Beam Therapeutics (BEAM) with a $43.00 price target. Dina Ramadane issued a Sell rating for ProKidney (PROK) with a $1.00 price target.
Beam Therapeutics (BEAM) released initial Phase 1/2 results for BEAM-301, showing dose-dependent effects and an acceptable safety profile, which led to a 4.67% share price increase in one day. Despite this, the year-to-date share price is down 8.25%, and the 5-year total shareholder return is significantly negative. The stock is currently trading at $24.90, which is considerably below a fair value estimate of $51.07, suggesting it is undervalued, but a high P/S ratio compared to the biotech average indicates investors are paying a premium for future potential.